Overview

Cardiovascular Improvements With MV ASV Therapy in Heart Failure

Status:
Terminated
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The aim of the study is to compare the effects of MV targeted ASV in addition to optimized medical therapy versus optimized medical therapy alone at 6 months in patients with acute decompensated HF. The study will also assess changes in functional parameters, biomarkers, quality of life (QOL), and sleep.
Phase:
N/A
Details
Lead Sponsor:
ResMed
Collaborator:
ResMed Foundation